Evidence map›Paper›PMID 39566935›Full record

ArticleBMJ open2024

Effectiveness and cost-effectiveness of guided self-help for depression for autistic adults: the Autism Depression Trial (ADEPT-2) - protocol for a multicentre, randomised controlled trial of a remotely delivered low-intensity intervention.

Holly Emily Mckeon, Leonora Cotton, Rona Aldridge, Alison Cape, Madeleine Clout, Kate Cooper, Dave Dagnan, Ed Dawn, Jessica Frost, Aikaterini Georgakopoulou and 16 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Holly Emily MckeonBristol Trials Centre, University of Bristol, Bristol, UK.
Leonora CottonBristol Trials Centre, University of Bristol, Bristol, UK.ORCID http://orcid.org/0009-0004-2107-0670
Rona AldridgeCardiff and Vale Integrated Autism Services, Cardiff and Vale University Health Board, Cardiff, UK.
Alison CapeAvon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.
Madeleine CloutBristol Trials Centre, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-7645-1199
Kate CooperDepartment of Psychology, University of Bath, Bath, UK.
Dave DagnanCommunity Learning Disability Team, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0002-5709-1586
Ed DawnPublic Contributors of ADEPT-2, Patient and Public Involvement Group, University of Bristol, Bristol, UK.
Jessica FrostBristol Trials Centre, University of Bristol, Bristol, UK.
Aikaterini GeorgakopoulouBristol Trials Centre, University of Bristol, Bristol, UK.
Kirsty GarfieldBristol Trials Centre, University of Bristol, Bristol, UK.
Jeremy HorwoodDepartment of Population Health Sciences, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-7092-4960
Barry InghamCommunity Learning Disability Team, Cumbria Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Vicky JervisDurham Tees Valley Adult Autism Team, Tees Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.
David KesslerDepartment of Population Health Sciences, University of Bristol, Bristol, UK.
Peter LangdonSocial Policy and Psychology, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-7745-1825
Chris MetcalfeBristol Trials Centre, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-8318-8907
Dheeraj RaiDepartment of Population Health Sciences, University of Bristol, Bristol, UK.
Alba RealpeBristol Trials Centre, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-9502-3907
Christine RussellPublic Contributors of ADEPT-2, Patient and Public Involvement Group, University of Bristol, Bristol, UK.
Hannah SheridanBristol Trials Centre, University of Bristol, Bristol, UK.
Karolina SlowinskaDepartment of Psychology, University of Bath, Bath, UK.
Joanna ThornBristol Trials Centre, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-8962-2428
Liping WenBristol Trials Centre, University of Bristol, Bristol, UK.
Nicola WilesDepartment of Population Health Sciences, University of Bristol, Bristol, UK.
Ailsa RussellDepartment of Psychology, University of Bath, Bath, UK a.j.russell@bath.ac.uk.ORCID http://orcid.org/0000-0002-8443-9381

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDepression is three to four times more prevalent in autistic people and is related to reduced quality of life. There is a need for empirically supported psychological interventions for depression specifically adapted to meet the needs of autistic adults. ADEPT-2 aims to establish the clinical and cost-effectiveness of an adapted low-intensity psychological intervention (guided self-help) for depression in autistic adults. METHODS AND ANALYSIS: A two parallel-group multicentre pragmatic randomised controlled trial investigating the effectiveness of GSH for depression in autistic adults. Participants (n=248) aged ≥18 years with a clinical diagnosis of autism currently experiencing depression will be randomised to GSH or treatment as usual (TAU). GSH is a low-intensity psychological intervention based on the principles of behavioural activation adapted for autism. GSH comprises informational materials for nine individual sessions facilitated online by a GSH coach who has received training and supervision in delivering the intervention. The primary outcome will be Beck Depression Inventory-II depression scores at 16 weeks post randomisation with follow-up measures at 32 and 52 weeks. Additional measures of anxiety, patient-rated global improvement, quality of life, work and social adjustment, positive and negative affect will be measured 16 and 52 weeks post randomisation. The primary health economic analysis will assess the cost-effectiveness of GSH compared with TAU over 52 weeks, from a societal perspective including the National Health Service, personal social services, personal expenses, voluntary services and productivity. An embedded qualitative study will explore the acceptability, experiences and adherence of participants and therapists to treatment principles. ETHICS AND DISSEMINATION: This trial has been approved by the East of England - Essex Research Ethics Committee on 10 June 2022 (REC Reference number: 22/EE/0091). The findings of the research will be submitted for publication in peer-reviewed journals and disseminated in an appropriate format to trial participants and the wider public. TRIAL REGISTRATION NUMBER: ISRCTN17547011.

Indexed as

Cost-Benefit AnalysisQuality of LifeAdultAutistic DisorderDepressionFemaleHumansMaleMulticenter Studies as TopicPragmatic Clinical Trials as TopicClinical TrialDepression & mood disordersPatient Reported Outcome Measures

Identifiers

PMID39566935
PMCPMC11580278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.